Old API Wind-down Ltd - Ordinary Shares ARLZQ

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Seeking alpha

[GoldenDilemma]

kuatolives wrote: You'd have to provide some concrete numbers on what you think are acceptable terms for the Toprol-XL deal, if these are not.  2x revenue for a drug that fits into their small portfolio sounds pretty good to me - and they nabbed the generic - and its unlikely any other generic will hit the market before the deal has well paid for itself due to the complexity of it. They could crack 150M in revenue in 2017 while turning a profit and you're thinking this was a bad idea? 

From a SA commentor:

"On the surface, a lot of people have surmised that part of the expected accretion of Toprol is piggybacking on the newly established, experienced 110 sales reps in the cardio field. Yet, Aralez has stated that they won't be utilizing their new reps to promote/sell Toprol, but will keep them exclusively focused on Yosprala, Zontivity etal. Thus Aralez has muted what many have assumed would be a synergistic promotion. I just wonder about that strategy, and how it appears that they are looking at Toprol as a self-sell, and how by virtue of that, they might be short changing themselves."

Some food for thought!